[1]Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J]. N Engl J Med, 2004, 351(13): 1296-1305.
[2]Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system [J]. Circulation, 2007, 116(1): 85-97.
[3]Brunet P, Gondouin B, Duval-Sabatier A, et al. Does uremia cause vascular dysfunction [J]? Kidney Blood Press Res, 2011, 34(4): 284-290.
[4]Massy ZA, Barreto DV, Barreto FC, et al. Uraemic toxins for consideration by the cardiologist-beyond traditional and non-traditional cardiovascular risk factors [J]. Atherosclerosis, 2010, 211(2): 381-383.
[5]Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins [J]. J Am Soc Nephrol, 2012, 23(7): 1258-1270.
[6]Vanholder R, Schepers E, Pletinck A, et al. An update on protein-bound uremic retention solutes [J]. J Ren Nutr, 2012, 22(1): 90-94.
[7]Lekawanvijit S, Kompa AR, Wang BH, et al. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins [J]. Circ Res, 2012, 111(11): 1470-1483.
[8]Feigenbaum J, Neuberg CA. Simplified method for the preparation of aromatic sulfuric acid esters [J]. J Am Chem Soc, 1941, 63(12): 3529-3530.
[9]Sun HQ, Zou ZhM, Chen YSh, et al. The effect of NDGA on gliomainduced endothelial tubular morphogenesisi and its mechanism [J]. Acta Anatomic Sinica, 2000, 31(4): 359-363. (in Chinese)
孙慧勤,邹仲敏,陈意生,等.去甲二氢愈创木酸对胶质瘤诱导的血管内皮细胞成型的作用[J].解剖学报,2000, 31(4): 359-363.
[10]Ross R. Atherosclerosis—an inflammatory disease [J]. N Engl J Med, 1999, 340(2): 115-126.
[11]Watanabe H, Miyamoto Y, Otagiri M, et al. Update on the pharmacokinetics and redox properties of protein-bound uremic toxins [J]. J Pharm Sci, 2011, 100(9): 3682-3695.
[12]Martinez AW, Recht NS, Hostetter TH, et al. Removal of P-cresol sulfate by hemodialysis [J]. J Am Soc Nephrol, 2005, 16(11): 3430-3436.
[13]Eloot S, Schepers E, Barreto DV, et al. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins [J]. Clin J Am Soc Nephrol, 2010, 6(6): 1266-1273.
[14]Lin CJ, Pan CF, Liu HL, et al. The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis [J]. Atherosclerosis, 2012, 225(1): 173-179.
[15]Wu IW, Hsu KH, Hsu HJ, et al. Serum free P-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients—a prospective cohort study [J]. Nephrol Dial Transplant, 2012, 27(3): 1169-1175.
[16]Vanholder R, Bammens B, de Loor H, et al. Warning: the unfortunate end of P-cresol as a uraemic toxin [J]. Nephrol Dial Transplant, 2011, 26(5): 1464-1467.
[17]Itoh Y, Ezawa A, Kikuchi K, et al. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ros production [J]. Anal Bioanal Chem, 2012, 403(7): 1841-1850.
[18]Viaene L, Evenepoel P, Meijers B, et al. Uremia suppresses immune signal-induced Cyp27b1 expression in human monocytes [J]. Am J Nephrol, 2012, 36(6): 497-508.
[19]Watanabe H, Miyamoto Y, Honda D, et al. P-cresyl sulfate causes renal tubular cell damage by inducing qxidative stress by activation of nadph oxidase [J]. Kidney Int, 2013, 83(4): 582-592.
|